Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose (NCT04815590) | Clinical Trial Compass
UnknownNot Applicable
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Canada40 participantsStarted 2022-10-17
Plain-language summary
This pilot study will evaluate the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among individuals at high-risk for overdose (OD).
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Be above 19 years of age;
ā. Be diagnosed with moderate or severe OUD as evidenced by their approval for treatment with XR-BUP (Sublocade);
ā. Be at high-risk for recurrent overdose, defined as having experienced a recent non-fatal overdose within the past 6 months (e.g., admission to the emergency department for an overdose OR self-reported OD that required Naloxone administration OR had an overdose where an ambulance arrived at the scene);
ā. Have a new prescription for XR-BUP, but have not yet initiated treatment;
ā. Be able and willing to follow study procedures;
ā. Be able to provide adequate locator information (e.g., phone number and at least one emergency contact);
ā. Be able and willing to provide written informed consent;
ā. Be able to understand, communicate and speak with the research staff. Non-English speaking individuals will require a translator to be present during all study visits and during all study activities. The translator will be independent (e.g., not known to the participant to prevent the risk for coercion or misrepresentation).
Exclusion criteria
ā. Be on OAT other than buprenorphine/naloxone in the 7 days prior to screening;
ā. Be on a stable buprenorphine/naloxone dose for more than 27 days prior to screening;
ā
What they're measuring
1
Number of XR-BUP injections received
Timeframe: 24 weeks
2
Proportion of treatment-engaged visits per participant